Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging (MR-O-MICS)

Institut du Cancer de Montpellier - Val d'Aurelle

Status

Enrolling

Conditions

High Grade Serous Ovarian Cancer

Treatments

Biological: Blood sample and tissue sample

Study type

Interventional

Funder types

Other

Identifiers

NCT06084195

PROICM 2023-02 MRO

Details and patient eligibility

About

The objective of this study is to explore the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cance

Full description

After being informed about the study and potential risks, all patient giving wirtting informed consent.

During surgery, tissue and blood samples will be conserved for the study. In this study will be compared images obtained in vivo before surgical management, ex vivo images obtained on excised tissues during surgery, histological data obtained during surgery.

Enrollment

120 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient aged >18
Pathologically proven HGSOC at an advanced stage (FIGO IIIB or IIIC) which can benefit from surgery with or without prior neoadjuvant treatment
Willingness and ability to comply with planned visits, treatment plan, laboratory tests and other study procedures,
Patient who has given informed, written and express consent,
Patient affiliated with a French health insurance scheme.

Exclusion criteria

Early-stage disease (FIGO <IIIB) or presence of extraperitoneal metastases,
Patient who will not have surgery
Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
Patient under guardianship, curatorship or safeguarding of justice,
Pregnant and/or nursing patient,
Patient with a history of other cancers within 5 years/10 years prior to inclusion